Evidence mapPaperPMID 36857036Full record

ArticleJAMA psychiatry2023

State Cannabis Legalization and Cannabis Use Disorder in the US Veterans Health Administration, 2005 to 2019.

Deborah S Hasin, Melanie M Wall, C Jean Choi, Daniel M Alschuler, Carol Malte, Mark Olfson, Katherine M Keyes, Jaimie L Gradus, Magdalena Cerdá, Charles C Maynard and 7 more

Open access · hybridAbstract read
In one paragraph

Article in JAMA psychiatry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
11.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 46 citations in OpenAlex.

  1. Identifying themes of protective behavioral strategies for marijuana use with structural topic modeling.Psychology of addictive behaviors : journal of the Society of Psychologists in Addictive Behaviors · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Drug interactions in a sample of inpatients diagnosed with cannabis use disorder.Journal of neural transmission (Vienna, Austria : 1996) · 2025
    Article
  12. Cannabis Use Among Older Adults.JAMA network open · 2025
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors at 7 institutions in 1 country.

Deborah S HasinColumbia University and New York State Psychiatric Institute, New York.
Melanie M WallColumbia University and New York State Psychiatric Institute, New York.
C Jean ChoiMental Health Data Science, New York State Psychiatric Institute, New York.
Daniel M AlschulerMental Health Data Science, New York State Psychiatric Institute, New York.
Carol MalteHealth Services Research & Development (HSR&D) Seattle Center of Innovation for Veteran-Centered and Value-Driven Care, Veterans Affairs (VA) Puget Sound Health Care System, Seattle, Washington.
Mark OlfsonColumbia University and New York State Psychiatric Institute, New York.
Katherine M KeyesColumbia University, New York, New York.
Jaimie L GradusBoston University, Boston, Massachusetts.
Magdalena CerdáNew York University, New York.
Charles C MaynardVA Puget Sound Health Care System and University of Washington, Seattle, Washington.
Salomeh KeyhaniSan Francisco VA Health System and University of California at San Francisco, San Francisco.
Silvia S MartinsColumbia University, New York, New York.
David S FinkNew York State Psychiatric Institute, New York.
Ofir LivneColumbia University, New York, New York.
Zachary MannesColumbia University, New York, New York.
Scott ShermanVA Manhattan Harbor Healthcare and New York University, New York.
Andrew J SaxonVA Puget Sound Health Care System and University of Washington, Seattle, Washington.
Columbia University · USNew York State Psychiatric InstituteNew York University · USUniversity of Washington · USNew York State Office of Mental Health · USSan Francisco VA Health Care System · USVA Puget Sound Health Care System · US

Funding

Impact of Medical and Recreational Marijuana Laws On Cannabis, Opioids And Psychiatric Medications: National Study of VA Patients, 2000 - 2024R01DA048860 · NIDA · NEW YORK STATE PSYCHIATRIC INSTITUTE DBA RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC · PI DEBORAH S HASIN · 2023 to 2023
$746k
NIDA NIH HHS K23 DA057417NIDA NIH HHS K99 DA055724NIDA NIH HHS R01 DA048860
6 · The paper itself

Abstract

Importance: Cannabis use disorder (CUD) is increasing among US adults. Few national studies have addressed the role of medical cannabis laws (MCLs) and recreational cannabis laws (RCLs) in these increases, particularly in patient populations with high rates of CUD risk factors. Objective: To quantify the role of MCL and RCL enactment in the increases in diagnosed CUD prevalence among Veterans Health Administration (VHA) patients from 2005 to 2019. Design, Setting, and Participants: Staggered-adoption difference-in-difference analyses were used to estimate the role of MCL and RCL in the increases in prevalence of CUD diagnoses, fitting a linear binomial regression model with fixed effects for state, categorical year, time-varying cannabis law status, state-level sociodemographic covariates, and patient age group, sex, and race and ethnicity. Patients aged 18 to 75 years with 1 or more VHA primary care, emergency department, or mental health visit and no hospice/palliative care within a given calendar year were included. Time-varying yearly state control covariates were state/year rates from American Community Survey data: percentage male, Black, Hispanic, White, 18 years or older, unemployed, income below poverty threshold, and yearly median household income. Analysis took place between February to December 2022. Main Outcomes and Measures: As preplanned, International Classification of Diseases, Clinical Modification, ninth and tenth revisions, CUD diagnoses from electronic health records were analyzed. Results: The number of individuals analyzed ranged from 3 234 382 in 2005 to 4 579 994 in 2019. Patients were largely male (94.1% in 2005 and 89.0% in 2019) and White (75.0% in 2005 and 66.6% in 2019), with a mean (SD) age of 57.0 [14.4] years. From 2005 to 2019, adjusted CUD prevalences increased from 1.38% to 2.25% in states with no cannabis laws (no CLs), 1.38% to 2.54% in MCL-only enacting states, and 1.39% to 2.56% in RCL-enacting states. Difference-in-difference results indicated that MCL-only enactment was associated with a 0.05% (0.05-0.06) absolute increase in CUD prevalence, ie, that 4.7% of the total increase in CUD prevalence in MCL-only enacting states could be attributed to MCLs, while RCL enactment was associated with a 1.12% (95% CI, 0.10-0.13) absolute increase in CUD prevalence, ie, that 9.8% of the total increase in CUD prevalence in RCL-enacting states could be attributed to RCLs. The role of RCL in the increases in CUD prevalence was greatest in patients aged 65 to 75 years, with an absolute increase of 0.15% (95% CI, 0.13-0.17) in CUD prevalence associated with RCLs, ie, 18.6% of the total increase in CUD prevalence in that age group. Conclusions and Relevance: In this study of VHA patients, MCL and RCL enactment played a significant role in the overall increases in CUD prevalence, particularly in older patients. However, consistent with general population studies, effect sizes were relatively small, suggesting that cumulatively, laws affected cannabis attitudes diffusely across the country or that other factors played a larger role in the overall increases in adult CUD. Results underscore the need to screen for cannabis use and CUD and to treat CUD when it is present.

Indexed as

CannabisHallucinogensMarijuana AbuseMedical MarijuanaSubstance-Related DisordersAdultAgedHumansMaleUnited StatesVeterans HealthHallucinogensMedical Marijuana

Identifiers

PMID36857036
PMCPMC9979011
OpenAlexW4322720166

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.